Clindesse Cream
NDC Package 45802-042-01
Package Information
Clindesse (clindamycin phosphate) cream is a medication used to treat a certain type of vaginal infection (bacterial vaginosis) in women who are not pregnant. This formulation utilizes a cream delivery system. Marketed by Padagis Israel Pharmaceuticals Ltd, this product is identified by NDC 45802-042 and is authorized under FDA application NDA050793.
Identification & Billing
- RxCUI: 309337 - clindamycin phosphate 2 % Vaginal Cream
- RxCUI: 309337 - clindamycin 20 MG/ML Vaginal Cream
- RxCUI: 309337 - clindamycin (as clindamycin phosphate) 2 % Vaginal Cream
- RxCUI: 309337 - clindamycin 2 % Vaginal Cream
- RxCUI: 602427 - Clindesse 2 % Vaginal Cream
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 45802 - Padagis Israel Pharmaceuticals Ltd
- 45802-042 - Clindesse
- 45802-042-01 - 1 APPLICATOR in 1 CARTON / 5 g in 1 APPLICATOR
- 45802-042 - Clindesse
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (45802-042). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 45802-042-01 identifies a specific commercial package of 1 applicator in 1 carton / 5 g in 1 applicator of Clindesse, a human prescription drug labeled by Padagis Israel Pharmaceuticals Ltd. This cream is formulated for vaginal use and contains clindamycin phosphate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Padagis Israel Pharmaceuticals Ltd on July 03, 2015. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This medication is used to treat a certain type of vaginal infection (bacterial vaginosis) in women who are not pregnant. Clindamycin is an antibiotic that works by stopping the growth of bacteria.
How is this Padagis Israel Pharmaceuticals Ltd product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 45802004201. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.